LOXAM/JCDECAUX
28.3.2017 16:42:10 CEST | Business Wire | Press release
In 2017, LOXAM, the European leader in the rental of equipment and tooling for building, public works and industry, is celebrating its 50th anniversary. In association with JCDecaux Artvertising, a vast fresco produced by the agency SuperCafard has been installed on the glass façade of its Group Headquarters at Porte Maillot, Paris. Spanning almost 500 square metres, this specially-created visual represents the vitality that has been the Group’s hallmark over the past 50 years.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170328006023/en/
This year LOXAM is celebrating its 50th , and is keen to tell the world. Founded in Brittany in 1967, the Group is today the European number one in equipment rental. This outstanding achievement is shared by the 7,500 employees in the company today, spread over 21 countries around the world. To produce and deploy a visual in keeping with the scale of the event, LOXAM selected the agency SuperCafard to design the graphics, and JCDecaux Artvertising – its long-standing partner in temporary display advertising – for the installation of the decal on the façade of its Paris offices.
Capitalising on the expertise and experience of the teams at JCDecaux Artvertising, the decal measuring nearly 500 square metres was installed in the space of three days by six abseilers. Five spotlights are trained on this visual, which will now be visible to more than 50,000 vehicles per day passing through the Place de la Porte Maillot between now and the end of June.
An exceptional anniversary deserves exceptional visibility at LOXAM!
About :
JCDecaux Artvertising
With prestigious and strategically-located locations, the full range of JCDecaux Artvertising’s special-build decal solutions provides brands with powerful assets with which to promote their image.
LOXAM
Loxam is the market leader in the rental of equipment and tooling for
building, public works and industry, with pro forma turnover of 1.3
billion euros in 2016 and a workforce of 7,500 employees. The Group
operates out of 21 countries around the world.
www.loxam.com
SuperCafard
SuperCafard, an independently-owned design agency, is proud to support LOXAM in a BIG celebration. For the 50th anniversary of the equipment rental company, SuperCafard thought big by recommending a visual on the scale of a major brand. Just like LOXAM, we are not afraid to magnify major projects, and we will always find the means to embody them.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170328006023/en/
Contact:
LOXAM press contact
Yannick DUVERGE,
Tel.: +33 6
89 44 64 07
yannick@relationpresse.com
or
JCDecaux
product communication press contact
Xavier GUEPET,
Tel.:
+33 1 30 79 34 48
xavier.guepet@jcdecaux.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release
ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release
Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom